In 2025, the CNS market is forecast to surpass $80bn in sales for the first time since 2013, marking a significant turnaround ...

A broad range of nanomedicines is being developed to improve drug delivery for CNS disorders. The structure of the blood-brain barrier (BBB), the presence of efflux pumps and the expression of ...

But medical professionals soon discovered these drugs, including methamphetamines, came with a high potential for addiction. The FDA approved a new central nervous system stimulant called ...

Results: CNS stimulants have psychotropic effects that may be perceived to be ergogenic. Some are prescription drugs, such as Ephedra alkaloids, and there are issues regarding their appropriate ...

chief medical officer of CNS Pharmaceuticals, “the fact that this study showed no cardiotoxicity with Berubicin, even in those receiving the drug for over a year, suggests Berubicin could be a ...

“I am delighted to serve as guest editor for the recently published CNS Drugs supplement, focused on key clinical issues for people with narcolepsy and their clinicians with a particular ...

“I am delighted to serve as guest editor for the recently published CNS Drugs supplement, focused on key clinical issues for people with narcolepsy and their clinicians with a particular ...

Increased risk for CNS adverse events (eg, hallucinations and confusion, cardiac events resulting in falls or other sequelae, drug-drug and drug-disease interactions) in elderly. Only use ...